This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Medivir (MVRB.F) Stock Overview

A pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. More details

MVRB.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 58.25% per year

Earnings have grown 41.9% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of 13.4% per year for the next 3 years

Shares are highly illiquid

Makes less than USD$1m in revenue (SEK4M)

Does not have a meaningful market cap ($422M)

+ 1 more risk

MVRB.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Medivir AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Medivir
Historical stock prices
Current Share Price	SEK 0.82
52 Week High	SEK 0.82
52 Week Low	SEK 0.68
Beta	0.35
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-47.10%
5 Year Change	n/a
Change since IPO	-85.53%

Recent updates

Shareholder Returns

	MVRB.F	US Biotechs	US Market
7D	0%	-1.7%	-2.5%
1Y	n/a	26.1%	22.7%

Return vs Industry: Insufficient data to determine how MVRB.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how MVRB.F performed against the US Market.

Price Volatility

Is MVRB.F's price volatile compared to industry and market?
MVRB.F volatility
MVRB.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.9%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: MVRB.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine MVRB.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1987	9	Jens Lindberg	www.medivir.com

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma.

Medivir AB (publ) Fundamentals Summary

How do Medivir's earnings and revenue compare to its market cap?
MVRB.F fundamental statistics
Market cap	US$40.89m
Earnings (TTM)	-US$7.26m
Revenue (TTM)	US$417.00k

98.0x

P/S Ratio

-5.6x

P/E Ratio

Is MVRB.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MVRB.F income statement (TTM)
Revenue	SEK 4.31m
Cost of Revenue	SEK 56.38m
Gross Profit	-SEK 52.07m
Other Expenses	SEK 22.90m
Earnings	-SEK 74.96m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

Aug 18, 2023

Earnings per share (EPS)	-1.35
Gross Margin	-1,208.68%
Net Profit Margin	-1,740.13%
Debt/Equity Ratio	0%

How did MVRB.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/05/01 14:45
End of Day Share Price	2023/02/01 00:00
Earnings	2023/03/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medivir AB (publ) is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kristofer Liljeberg-Svensson	Carnegie Investment Bank AB
Mattias Häggblom	Danske Bank
Klas Palin	DNB Carnegie Commissioned Research

Medivir AB (publ)OTCPK:MVRB.F Stock Report